Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea

This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.

Inclusion Criteria:

• Girls ages 9 to 15 years (must not yet have had coitarche)
• Healthy females ages 16 to 23 years (individuals with a lifetime history of 0 to 3 male or female sexual partners)

Exclusion Criteria:

All Subjects:

• History of known prior vaccination with an HPV vaccine.

Women Ages 16 to 23 Only:

• Individuals with any prior history of genital warts or treatment for genital warts.
• Individuals with > 3 lifetime male or female sexual partners.